ReviewJournal of clinical and experimental hematopathology : JCEH2026
Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.
Review in Journal of clinical and experimental hematopathology : JCEH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma characterized by a relapsing clinical course. Recently, CD20×CD3 bispecific antibodies, including mosunetuzumab, have emerged as effective therapeutic options for relapsed or refractory FL. However, their efficacy in malignant effusions, including pleural effusion, remains unclear. We report a case of relapsed FL complicated by chylothorax that showed a rapid response to mosunetuzumab. A 74-year-old woman with a history of FL, initially treated with R-CHOP and later with rituximab monotherapy, presented with progressive dyspnea and was found to have bilateral pleural effusion. Analysis of pleural fluid revealed chylothorax with infiltration of CD20-positive lymphoma cells, confirmed by flow cytometry and cell-block immunohistochemistry. Following initiation of mosunetuzumab, pleural effusion decreased promptly, with a marked reduction in lymphoma cells in the pleural fluid observed as early as day 2. The patient achieved a complete metabolic response on positron emission tomography-computed tomography (PET-CT) after eight cycles of therapy. This case suggests that mosunetuzumab may exert rapid antitumor activity in both systemic disease and malignant effusions, possibly through distribution into pleural fluid and subsequent T-cell-mediated cytotoxicity. Further studies are warranted to clarify the role of bispecific antibodies in malignant effusions associated with lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.